HF
HRTX icon

HRT Financial’s Heron Therapeutics HRTX Stock Holding History

HRT Financial’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11K Buy
+27,024
New +$21.7K ﹤0.01% 3979
2025
Q2 		– Sell
-29,231
Closed -$64K – 3022
2025
Q1 		$64K Buy
+29,231
New +$56.7K ﹤0.01% 2212
2024
Q4 		– Sell
-426,817
Closed -$849K – 2747
2024
Q3 		$849K Buy
+426,817
New +$1.02M ﹤0.01% 1326
2024
Q1 		– Sell
-199,908
Closed -$339K – 2632
2023
Q4 		$339K Buy
+199,908
New +$220K ﹤0.01% 1566
2023
Q2 		– Sell
-547,365
Closed -$826K – 2799
2023
Q1 		$826K Buy
547,365
+107,981
+25% +$270K 0.01% 1050
2022
Q4 		$1.1M Buy
439,384
+58,943
+15% +$190K 0.02% 900
2022
Q3 		$1.6M Buy
+380,441
New +$1.49M 0.02% 691
2022
Q1 		– Sell
-37,662
Closed -$343K – 3409
2021
Q4 		$343K Buy
+37,662
New +$385K ﹤0.01% 2172

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

HRT Financial's HRTX Position: Q2 2026 in Review

HRT Financial opened a new position in Heron Therapeutics (HRTX) in Q2 2026: 27,024 shares worth $11K. The stake represents ﹤0.01% of the portfolio and ranks #3979 among its holdings. This is a return to the name: HRT Financial previously reported a position in HRTX as recently as Q1 2025.

HRT Financial first reported a position in HRTX in Q4 2021 and has held it in 8 quarters since. The position peaked at $1.6M in Q3 2022. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • HRT Financial held 27,024 shares of Heron Therapeutics worth $11K as of Q2 2026.
  • Heron Therapeutics was a new HRT Financial position in Q2 2026.
  • Heron Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q2 2026, its #3979 holding.
  • HRT Financial first reported a position in Heron Therapeutics in Q4 2021 and has held it in 8 quarters since.
  • HRT Financial's Heron Therapeutics position peaked at $1.6M in Q3 2022.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.